Follow
Hareth Al-Wassiti
Title
Cited by
Cited by
Year
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley, D Zukancic, ...
Acta biomaterialia 131, 16-40, 2021
1702021
Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay
SLY Teo, JJ Rennick, D Yuen, H Al-Wassiti, APR Johnston, CW Pouton
Nature Communications 12 (1), 3721, 2021
832021
The importance of poly (Ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles
D Zukancic, EJA Suys, EH Pilkington, A Algarni, H Al-Wassiti, NP Truong
Pharmaceutics 12 (11), 1068, 2020
572020
In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression
A Algarni, EH Pilkington, EJA Suys, H Al-Wassiti, CW Pouton, NP Truong
Biomaterials Science 10 (11), 2940-2952, 2022
412022
Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection
A Takanashi, CW Pouton, H Al-Wassiti
Molecular Pharmaceutics 20 (8), 3876-3885, 2023
72023
Unravelling cytosolic delivery of endosomal escape peptides with a quantitative endosomal escape assay (SLEEQ)
SLY Teo, JJ Rennick, D Yuen, H Al-Wassiti, APR Johnston, CW Pouton
BioRxiv, 2020.08. 20.258350, 2020
72020
The mRNA vaccine technology era and the future control of parasitic infections
H You, MK Jones, CA Gordon, AE Arganda, P Cai, H Al-Wassiti, ...
Clinical Microbiology Reviews 36 (1), e00241-21, 2023
52023
Adenovirus terminal protein contains a bipartite nuclear localisation signal essential for its import into the nucleus
HA Al-Wassiti, DR Thomas, KM Wagstaff, SA Fabb, DA Jans, AP Johnston, ...
International Journal of Molecular Sciences 22 (7), 3310, 2021
42021
Assessing the cellular toxicity of peptide inhibitors of intracellular protein-protein interactions by microinjection
SB Reddiar, H Al-Wassiti, CW Pouton, CJ Nowell, MA Matthews, ...
Bioorganic & Medicinal Chemistry 29, 115906, 2021
42021
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose …
TM Nolan, G Deliyannis, M Griffith, S Braat, LF Allen, J Audsley, ...
EBioMedicine 98, 2023
22023
mRNA vaccines encoding membrane-anchored receptor-binding domains of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting
HA Al-Wassiti, SA Fabb, SL Grimley, R Kochappan, JK Ho, CY Wong, ...
bioRxiv, 2023.10. 04.560777, 2023
2023
Non-viral gene delivery agent comprising lipopeptide (LP) compounds
CW Pouton, KTJ Ho, PJ White, CT Bui, N Akhtar, HA Al-wassiti
US Patent 11,446,393, 2022
2022
mRNA therapy: a new form of gene medicine
H Al-Wassiti
2019
Towards a Non-Viral Gene Delivery Platform That Emulates the Mechanism Used to Deliver the Adenoviral Genome
H Al-Wassiti, DR Thomas, S Fabb, A Johnston, C Pouton
MOLECULAR THERAPY 25 (5), 324-325, 2017
2017
Lonafarnib is an oral medication that helps prevent the buildup of defective progerin or progerin-like protein. Menu
SB Reddiar, H Al-Wassiti, CW Pouton, CJ Nowell, MG Matthews, ...
Towards A Novel Non-Viral Gene Delivery System Based On Adenovirus Genome
HBALI AL-WASSITI
Monash University, 0
The system can't perform the operation now. Try again later.
Articles 1–16